Key Developments: Ranbaxy Laboratories Ltd (RANB.BO)
409.20INR
5:00am EST
Rs3.65 (+0.90%)
Rs405.55
Rs410.00
Rs414.60
Rs403.50
304,136
245,712
Rs538.00
Rs133.15
Latest Key Developments
FDA Tells Ranbaxy Laboratories Limited To Assess Plants-Reuters
Reuters reported that according to The Economic Times report, The U.S. drug regulator has asked Ranbaxy Laboratories Limited to immediately assess whether its plants making drugs for the U.S. market meet standards.
Ranbaxy Laboratories Limited Announces Acquisition Of Product Rights And Manufacturing Facility From Biovel Lifesciences Private Limited
Ranbaxy Laboratories Limited announced the signing of agreements with Biovel Lifesciences Private Limited (Biovel), Bangalore, India, providing for the acquisition of product rights and a manufacturing facility, from Biovel. The proposed transaction will give Ranbaxy access to all of Biovel's products, pipeline, IP, Know how and manufacturing facility, located in Bangalore, India. The products that are part of the transaction include Typhoid Vi antigen and Hib conjugate vaccines, for which, Biovel has received regulatory approval for India.
Ranbaxy Laboratories Limited In Talks To Acquire Bangalore Vaccine Company-DJ
Dow Jones reported that Ranbaxy Laboratories Limited is in talks to buy a privately owned vaccine company based in Bangalore. The deal could be worth around INR500 million ($10.8 million).
Ranbaxy Laboratories Limited Launches New Chemical Entity, Llifin In India
Ranbaxy Laboratories Limited announced that the Company has launched a New Chemical Entity, Lulifin (Luliconazole), in the Indian Dermatology market. This follows a strategic in licensing agreement with Summit Pharmaceuticals International Corporation, Japan allowing Ranbaxy, exclusive marketing rights, for India.
Ranbaxy Laboratories Limited To Transfer Stake In Ranbaxy (Guangzhou China) Limited To HNG Chembio Pharmacy Co. Ltd.
Ranbaxy Laboratories Limited announced the transfer of Ranbaxy group's entire shareholding in Ranbaxy (Guangzhou China) Limited to HNG Chembio Pharmacy Co. Ltd. Ranbaxy (Guangzhou China) Limited was a joint venture between the Ranbaxy group, Guangzhou Baiyunshan Pharmaceutical Company Limited, Guangzhou, China and Hong Kong New Chemic, Hong Kong. This transaction is part of Ranbaxy's endeavour to develop a new business model for China which entails the marketing of value added pharmaceutical formulations and the consolidation of manufacturing operations, for cost synergies.
Ranbaxy Laboratories Limited Says US Unit Gets Violations Notice-Reuters
Reuters reported that Ranbaxy Laboratories Limited said its wholly owned U.S.-based unit Ohm Laboratories Inc has received a warning letter from the U.S. Food and Drug Administration (FDA) relating to violations of good manufacturing practices. The FDA letter, dated December 21, mentions violations at Ohm's liquid manufacturing facility in Gloversville, New York, Ranbaxy said in a statement after markets closed. The FDA conducted site inspections at the plant in July and August 2009. The Company will continue to cooperate with the US FDA to bring the matter to closure in a timely manner and remains committed in its efforts to be fully compliant with US regulatory standards, Ranbaxy said. Ohm has retained global consulting firm PRTM Inc to advise on issues cited by the FDA, it said.
Ranbaxy Laboratories Limited And Daiichi Sankyo Company Limited Announces Marketing And Distribution Of Olmesartan In Six African Countries
Ranbaxy Laboratories Limited and Daiichi Sankyo Company Limited announced that Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries; Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia. The companies will launch the products under the brand name Olvance, as soon as the necessary measure have been completed in each county.
Ranbaxy Laboratories Limited To Launch Flomax Generic In March-Reuters
Reuters reported that Ranbaxy Laboratories Limited expects to launch a generic version of Astellas Pharma's Flomax urinary drug in March next year.
Ranbaxy Laboratories Limited Won't Sell Generic Version Of Purdue Drug-DJ
Dow Jones reported that Ranbaxy Laboratories Limited won't go ahead with its plans to make and sell a generic version of Purdue Pharma LP's OxyContin painkiller, the Financial Chronicle reported, without citing any sources. Ranbaxy Laboratories Limited and its units, which Purdue sued in October for patent infringements, admitted in a U.S. district court in New York last week that their Food & Drug Administration application to sell a generic version of OxyContin infringed a Purdue patent, the report said. The court gave a consent judgment, dismissing Purdue's suit without costs and asking Ranbaxy Laboratories Limited to refrain from infringing on the patent. Ranbaxy Laboratories Limited agreed also not to seek FDA approval to market generic versions of OxyContin until the expiry of the patent and any period of marketing exclusivity, the report said, citing an unnamed expert on patent laws.
Ranbaxy Laboratories Limited And Nippon Chemiphar Dissolve Their Joint Venture Nihon Pharmaceutical Industry Co. Ltd In Japan
Ranbaxy Laboratories Limited and Nippon Chemiphar announced the dissolution of their joint venture Nihon Pharmaceutical Industry Co. Ltd, in Japan. This follows an agreement between the two companies that allows Nippon Chemiphar to purchase the entire shareholding of its erstwhile partner. Both companies held equal shares in the joint venture. Following the transaction, Nihon Pharmaceutical Industry will become a wholly owned subsidiary of Nippon Chemiphar. The financial terms of the agreement were not disclosed.
US FDA tells India Ranbaxy to assess plants-report
NEW DELHI, Feb 5 (Reuters) - The U.S. drug regulator has asked India's Ranbaxy Laboratories to immediately assess whether its plants making drugs for the U.S. market meet standards, the Economic Times newspaper reported on Friday.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
